Holen Sie sich die Stockscreener-App
441.20
1.27%
5.55
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$435.65
Offen:
$441.55
24-Stunden-Volumen:
1.03M
Relative Volume:
0.71
Marktkapitalisierung:
$112.22B
Einnahmen:
$12.07B
Nettoeinkommen (Verlust:
$3.95B
KGV:
28.77
EPS:
15.3349
Netto-Cashflow:
$3.19B
1W Leistung:
+1.13%
1M Leistung:
-4.60%
6M Leistung:
+5.85%
1J Leistung:
-9.79%
1-Tages-Spanne:
$437.58
$443.90
1-Wochen-Bereich:
$431.15
$447.82
52-Wochen-Spanne:
$362.50
$510.77
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-03-10 | Bestätigt | Oppenheimer | Outperform |
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
GF Fund Management CO. LTD. Raises Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stock Position Lifted by Asset Management One Co. Ltd. - MarketBeat
Morgan Stanley Lifts Vertex Pharmaceuticals (VRTX) PT on Updated Biopharma Models - Insider Monkey
Lightning round: Buy Vertex Pharmaceuticals - MSN
Lightning Round: Buy Vertex Pharmaceuticals - CNBC
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex (VRTX) director receives new deferred stock unit grant - Stock Titan
VRTX Stock Quote Price and Forecast - CNN
Vertex (NASDAQ: VRTX) director granted 107 deferred stock units as equity pay - Stock Titan
Vertex (VRTX) board member receives deferred stock unit award - Stock Titan
Vertex Pharma stock (US92532F1003): Is cystic fibrosis dominance still enough for long-term upside? - AD HOC NEWS
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Mirae Asset Global Investments Co. Ltd. - MarketBeat
KBC Group NV Acquires 7,518 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Vertex’s IgAN drug outlook strengthens on positive phase 3 data - S&P Global
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Vertex Pharmaceuticals' Empire in Trouble? - AOL.com
Is Vertex Pharmaceuticals' Empire in Trouble? - The Motley Fool
Vertex Pharmaceuticals Incorporated : 2025 Data Summary - marketscreener.com
Vertex price returns lowerForecast today16-04-2026 - Economies.com
Morgan Stanley Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Lbp Am Sa Acquires 22,918 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (STU:VX1) Stock Price & 30 Year Financial Data - GuruFocus
Vertex Pharmaceuticals: Solid CF Franchise and Emerging Pipeline Support Buy Rating and Premium Valuation - TipRanks
Zealand Pharma appoints US-based investor relations head - medwatch.com
5 biopharma M&A deals where the workforce was the prize - BioSpace
Vertex Sues Former Exec To Block Move To Rival - Law360
Baillie Gifford Trims Vertex Pharmaceuticals Stake - National Today
15,717 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Third View Private Wealth LLC - MarketBeat
Massachusetts Financial Services Co. MA Sells 291,226 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baillie Gifford & Co. Has $91.17 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026 - Investing.com UK
Hardman Johnston Global Advisors LLC Sells 15,346 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Andrew Hill Investment Advisors Inc. - MarketBeat
Sumitomo Mitsui Trust Group Reduces Vertex Pharmaceuticals Stake - National Today
Robeco Institutional Asset Management B.V. Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley - Yahoo Finance
Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways - Sahm
4,828 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Fiduciary Alliance LLC - MarketBeat
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Promising Biotech Stocks To Follow TodayApril 10th - MarketBeat
Vertex Pharmaceuticals (VRTX) Analyst Rating Update: Price Targe - GuruFocus
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $612 - Moomoo
RBC Trims Price Target on Vertex Pharmaceuticals to $541 From $543, Keeps Outperform Rating - marketscreener.com
What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report - Yahoo Finance
Vertex licenses Halozyme’s Hypercon platform in $15 million deal - Новости GxP
V Square Quantitative Management LLC Acquires New Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
OFI Invest Asset Management Buys 68,832 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
3.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):